Your browser doesn't support javascript.
loading
The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma.
Maeda, Takuya; Yoshino, Koji; Nagai, Kojiro; Oaku, Satoe; Kato, Megumi; Hiura, Azusa; Hata, Hiroo.
Afiliación
  • Maeda T; a Department of Dermatologic Oncology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
  • Yoshino K; a Department of Dermatologic Oncology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
  • Nagai K; a Department of Dermatologic Oncology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
  • Oaku S; a Department of Dermatologic Oncology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
  • Kato M; a Department of Dermatologic Oncology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
  • Hiura A; a Department of Dermatologic Oncology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
  • Hata H; b Department of Dermatology , Faculty of Medicine and Graduate School of Medicine Hokkaido University , Sapporo , Japan.
Acta Oncol ; 58(3): 379-381, 2019 Mar.
Article en En | MEDLINE | ID: mdl-30614355
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Receptor de Muerte Celular Programada 1 / Ipilimumab / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Receptor de Muerte Celular Programada 1 / Ipilimumab / Melanoma Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Japón